Enhancing melanoma treatment with resveratrol

Gregory W. Osmond, Christina K. Augustine, Patricia A. Zipfel, James Padussis, Douglas Tyler

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Resveratrol (RESV) is a naturally occurring compound that possesses anti-cancer capabilities. The goal of this study was to evaluate the potential of RESV as an adjunct to chemotherapy in melanoma treatment. Methods: The in vitro and in vivo cytotoxic activity of RESV with or without chemotherapy was tested using cellular assays and a xenograft model. Two Duke melanoma cell lines (DM738, DM443) were used for both in vivo and in vitro experiments, and two nonmalignant human fibroblast lines (NHDF, HS68) were used for in vitro cellular assays. Xenografts were randomized to treatment arms and tumors measured to evaluate response. Results were analyzed using a Student's t-test and ANOVA. Western blots were performed on in vivo tissue. Results: In vitro RESV significantly decreased melanoma cell viability in all lines tested (all P < 0.0001). Treatment of fibroblast cell lines revealed that RESV selectively spared NHDF and HS68 cells compared with its cytotoxic effects on melanoma cells (P < 0.0001). Treatment of malignant cells with 50 μM RESV and temozolomide (TMZ) for 72 h significantly enhanced cytotoxicity compared with treatment with TMZ alone (P < 0.0001). In vivo, however, there was no significant difference between any treatment arms (P = 0.65). Conclusion: RESV shows promise as a novel therapeutic in the management of melanoma for its selective anti-tumor activity in vitro. Translating in vitro results to in vivo models has proven difficult. Barriers thought to prevent such translation are identified, and a rationale for overcoming them is discussed.

Original languageEnglish (US)
Pages (from-to)109-115
Number of pages7
JournalJournal of Surgical Research
Volume172
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Melanoma
temozolomide
Heterografts
Therapeutics
Arm
Fibroblasts
Drug Therapy
Cell Line
Neoplasms
resveratrol
In Vitro Techniques
Cell Survival
Analysis of Variance
Western Blotting
Students

Keywords

  • melanoma
  • melphalan
  • resveratrol
  • temozolomide

ASJC Scopus subject areas

  • Surgery

Cite this

Osmond, G. W., Augustine, C. K., Zipfel, P. A., Padussis, J., & Tyler, D. (2012). Enhancing melanoma treatment with resveratrol. Journal of Surgical Research, 172(1), 109-115. https://doi.org/10.1016/j.jss.2010.07.033

Enhancing melanoma treatment with resveratrol. / Osmond, Gregory W.; Augustine, Christina K.; Zipfel, Patricia A.; Padussis, James; Tyler, Douglas.

In: Journal of Surgical Research, Vol. 172, No. 1, 01.2012, p. 109-115.

Research output: Contribution to journalArticle

Osmond, GW, Augustine, CK, Zipfel, PA, Padussis, J & Tyler, D 2012, 'Enhancing melanoma treatment with resveratrol', Journal of Surgical Research, vol. 172, no. 1, pp. 109-115. https://doi.org/10.1016/j.jss.2010.07.033
Osmond, Gregory W. ; Augustine, Christina K. ; Zipfel, Patricia A. ; Padussis, James ; Tyler, Douglas. / Enhancing melanoma treatment with resveratrol. In: Journal of Surgical Research. 2012 ; Vol. 172, No. 1. pp. 109-115.
@article{84f7115530f4441798941647b0fdc96d,
title = "Enhancing melanoma treatment with resveratrol",
abstract = "Background: Resveratrol (RESV) is a naturally occurring compound that possesses anti-cancer capabilities. The goal of this study was to evaluate the potential of RESV as an adjunct to chemotherapy in melanoma treatment. Methods: The in vitro and in vivo cytotoxic activity of RESV with or without chemotherapy was tested using cellular assays and a xenograft model. Two Duke melanoma cell lines (DM738, DM443) were used for both in vivo and in vitro experiments, and two nonmalignant human fibroblast lines (NHDF, HS68) were used for in vitro cellular assays. Xenografts were randomized to treatment arms and tumors measured to evaluate response. Results were analyzed using a Student's t-test and ANOVA. Western blots were performed on in vivo tissue. Results: In vitro RESV significantly decreased melanoma cell viability in all lines tested (all P < 0.0001). Treatment of fibroblast cell lines revealed that RESV selectively spared NHDF and HS68 cells compared with its cytotoxic effects on melanoma cells (P < 0.0001). Treatment of malignant cells with 50 μM RESV and temozolomide (TMZ) for 72 h significantly enhanced cytotoxicity compared with treatment with TMZ alone (P < 0.0001). In vivo, however, there was no significant difference between any treatment arms (P = 0.65). Conclusion: RESV shows promise as a novel therapeutic in the management of melanoma for its selective anti-tumor activity in vitro. Translating in vitro results to in vivo models has proven difficult. Barriers thought to prevent such translation are identified, and a rationale for overcoming them is discussed.",
keywords = "melanoma, melphalan, resveratrol, temozolomide",
author = "Osmond, {Gregory W.} and Augustine, {Christina K.} and Zipfel, {Patricia A.} and James Padussis and Douglas Tyler",
year = "2012",
month = "1",
doi = "10.1016/j.jss.2010.07.033",
language = "English (US)",
volume = "172",
pages = "109--115",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Enhancing melanoma treatment with resveratrol

AU - Osmond, Gregory W.

AU - Augustine, Christina K.

AU - Zipfel, Patricia A.

AU - Padussis, James

AU - Tyler, Douglas

PY - 2012/1

Y1 - 2012/1

N2 - Background: Resveratrol (RESV) is a naturally occurring compound that possesses anti-cancer capabilities. The goal of this study was to evaluate the potential of RESV as an adjunct to chemotherapy in melanoma treatment. Methods: The in vitro and in vivo cytotoxic activity of RESV with or without chemotherapy was tested using cellular assays and a xenograft model. Two Duke melanoma cell lines (DM738, DM443) were used for both in vivo and in vitro experiments, and two nonmalignant human fibroblast lines (NHDF, HS68) were used for in vitro cellular assays. Xenografts were randomized to treatment arms and tumors measured to evaluate response. Results were analyzed using a Student's t-test and ANOVA. Western blots were performed on in vivo tissue. Results: In vitro RESV significantly decreased melanoma cell viability in all lines tested (all P < 0.0001). Treatment of fibroblast cell lines revealed that RESV selectively spared NHDF and HS68 cells compared with its cytotoxic effects on melanoma cells (P < 0.0001). Treatment of malignant cells with 50 μM RESV and temozolomide (TMZ) for 72 h significantly enhanced cytotoxicity compared with treatment with TMZ alone (P < 0.0001). In vivo, however, there was no significant difference between any treatment arms (P = 0.65). Conclusion: RESV shows promise as a novel therapeutic in the management of melanoma for its selective anti-tumor activity in vitro. Translating in vitro results to in vivo models has proven difficult. Barriers thought to prevent such translation are identified, and a rationale for overcoming them is discussed.

AB - Background: Resveratrol (RESV) is a naturally occurring compound that possesses anti-cancer capabilities. The goal of this study was to evaluate the potential of RESV as an adjunct to chemotherapy in melanoma treatment. Methods: The in vitro and in vivo cytotoxic activity of RESV with or without chemotherapy was tested using cellular assays and a xenograft model. Two Duke melanoma cell lines (DM738, DM443) were used for both in vivo and in vitro experiments, and two nonmalignant human fibroblast lines (NHDF, HS68) were used for in vitro cellular assays. Xenografts were randomized to treatment arms and tumors measured to evaluate response. Results were analyzed using a Student's t-test and ANOVA. Western blots were performed on in vivo tissue. Results: In vitro RESV significantly decreased melanoma cell viability in all lines tested (all P < 0.0001). Treatment of fibroblast cell lines revealed that RESV selectively spared NHDF and HS68 cells compared with its cytotoxic effects on melanoma cells (P < 0.0001). Treatment of malignant cells with 50 μM RESV and temozolomide (TMZ) for 72 h significantly enhanced cytotoxicity compared with treatment with TMZ alone (P < 0.0001). In vivo, however, there was no significant difference between any treatment arms (P = 0.65). Conclusion: RESV shows promise as a novel therapeutic in the management of melanoma for its selective anti-tumor activity in vitro. Translating in vitro results to in vivo models has proven difficult. Barriers thought to prevent such translation are identified, and a rationale for overcoming them is discussed.

KW - melanoma

KW - melphalan

KW - resveratrol

KW - temozolomide

UR - http://www.scopus.com/inward/record.url?scp=82955194712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955194712&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2010.07.033

DO - 10.1016/j.jss.2010.07.033

M3 - Article

VL - 172

SP - 109

EP - 115

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -